CNCE
Concert Pharmaceuticals, Inc.
CNCE
CNCE
Delisted
CNCE was delisted on the 3rd of March, 2023.
92 hedge funds and large institutions have $215M invested in Concert Pharmaceuticals, Inc. in 2019 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 34 increasing their positions, 31 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
92
Holders Change
-1
Holders Change %
-1.08%
% of All Funds
1.99%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
34
Reduced
31
Closed
13
Calls
$3.45M
Puts
$2.44M
Net Calls
+$1.01M
Net Calls Change
+$1.26M
Top Buyers
| 1 |
RI
RTW Investments
New York
|
+$10.9M |
| 2 |
PA
Perceptive Advisors
New York
|
+$3.99M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$2.84M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.44M |
| 5 |
Barclays
London,
United Kingdom
|
+$1.02M |
Top Sellers
| 1 |
First Manhattan
New York
|
-$7.2M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$6.99M |
| 3 |
Millennium Management
New York
|
-$2.23M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.46M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.33M |
